Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...
SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...
Rilzabrutinib, a BTK inhibitor, is approved for ITP, showing significant efficacy in improving platelet response and reducing bleeding symptoms. The LUNA 3 study demonstrated rilzabrutinib's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results